"Once a diagnosis is made, many patients with low risk disease can be safely monitored conservatively," Loeb said. "Menshould be actively involved in all of these choices, with a discussion about risks and benefits." What's really needed, according to Kavoussi, is a screen that can tell a...
J Urol. 2008 May;179(5):1756-1761; discussion 1761. 摘要 目的:前列腺特异性抗原,前列腺特异性抗原密度和 过渡区密度先前已被确定为前列腺癌检测标志物.最 近的研究表明,前列腺特异性抗原对于检测临床上显 著的高级别前列腺癌(格里森 7 级或更高)越来越准 确.我们研究了这些检测在接受前列腺活检计划的转...
High-risk patients (those with a positive family history or those of African American descent) are advised to begin screening at age 45. The decision to screen is based on the patient's preference following a thorough discussion of the benefits and limitations of PSA testing. Refer to a uro...
2024 Select Your Interests Others Also Liked Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer Eveline A M Heijnsdijk, JNCI: Journal of the National Cancer Institute, 2020 Early Detection of Prostate Cancer: The European Randomized Study of...
In addition, physicians should not screen patients unless the individual expresses a clear preference for screening following a discussion of benefits and harms. Men at an average risk for disease should not be screened if they are younger than 50 years or older than 69 years, nor should men ...
The current USPSTF PSA screening policy is slightly changed, with a grade C recommendation for men aged 55 to 69 years, meaning in this population, an individual decision on screening should be made based on a physician-clinician discussion of the potential benefits and risks. While the U...
Widespread use of PSA testing has contributed to the detection and overtreatment of men with low-risk, non-aggressive prostate cancer. Nevertheless, recognizing the benefits of PSA testing, the AUA updated its guidelines in 2013 to incorporate a man’s health risk, age, race, and family history...
accompanying editorial from Sloan Kettering Cancer Center hopes that this paper will put to rest the question of whether PSA screening reducesprostate cancer mortality. Instead, the discussion should focus on how to implement screening so that the benefit outweighs the harms of overdiagnosis and ...
Brawley said, "If I were talking to a patient today, I would explain to them the risks and benefits differently and with more confidence than I would have explained it to them in 2010." Studies like this have led groups on either side of the debate to meet in the middle, he added. ...
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur. Urol. 2020, 77, 614–627. [Google Scholar] [CrossRef] [PubMed] Berkovic, P.; De Meerleer, G.; Delure, L.; Lambert, B.; Font...